IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$423.65 USD
-6.17 (-1.44%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $423.84 +0.19 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$423.65 USD
-6.17 (-1.44%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $423.84 +0.19 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
Zacks News
Masimo RAS-45 Full-Market Release to Boost Respiratory Care
by Zacks Equity Research
Masimo Corporation's (MASI) newly launched RAS-45, a single use adhesive respiration sensor would strengthen the company's foothold in the growing global respiratory care market.
Baxter Announces Launch of DeviceVue System for Sigma Pumps
by Zacks Equity Research
Baxter's (BAX) latest development is expected to fortify its foothold in the smart pumps market.
Here's Why Mazor Robotics (MZOR) Stock Is Worth a Bet Now
by Zacks Equity Research
The market is upbeat about Mazor Robotics' (MZOR) recent CE Mark approval for Mazor X Surgical Assurance platform.
STERIS (STE) Rides on Organic Growth, Stiff Contest a Threat
by Zacks Equity Research
STERIS' (STE) consistent strong organic all-segment growth performance impresses investors. Additionally, growth in free cash flow reserve denotes the company's solid cash position.
Here's Why You Should Invest in Orthofix International Now
by Zacks Equity Research
Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation.
Allscripts Rides High on Product Launches Amid Rising Costs
by Zacks Equity Research
Management at Allscripts Healthcare (MDRX) is focused on various restructuring initiatives, research and development plans and launch of exclusive products.
Omnicell (OMCL) Gains on Product Launches, Global Expansion
by Zacks Equity Research
The market is upbeat about Omnicell's (OMCL) recently-launched XT Series Automated Supply Dispensing Cabinet. The company is also expanding its footprint globally.
Align Technology (ALGN) Prospects Bright, Competition Rife
by Zacks Equity Research
Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.
Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife
by Zacks Equity Research
Cerner's (CERN) stable position provides solid growth opportunities in the revenue cycle management (RCM) suite of solutions.
PetMed Express Optimistic on New Orders Amid Stiff Rivalry
by Zacks Equity Research
PetMed is striving to implement several strategies to revitalize its top line. Yet a highly competitive market poses threats.
Here's Why Investors Should Buy Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) announced 510(k) clearance and full-market release of its proprietary Rad-97 Pulse CO-Oximeter earlier this month.
Amedisys or Chemed: Which is a Better Investment Choice?
by Zacks Equity Research
After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).
Why Should Investors Add Amedisys (AMED) to Their Portfolio?
by Zacks Equity Research
Amedisys (AMED) rides high on solid prospects with new opportunities within home health and hospice services segments.
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
by Zacks Equity Research
IDEXX Laboratories (IDXX) continues to boost investor's confidence with strong companion animal business along with balanced growth across all segments.
Why is Edwards Lifesciences (EW) a Strong Buy Stock Now?
by Zacks Equity Research
Several recent FDA product-approvals boost investors' trust in Edwards Lifesciences' (EW) stock.
Here's Why You Should Add Chemed (CHE) to Your Portfolio
by Zacks Equity Research
Chemed (CHE) bolsters investor's confidence with continued strength in Roto-Rooter business.
Here's Why You Should Bet on BioTelemetry (BEAT) Stock Now
by Zacks Equity Research
BioTelemetry's (BEAT) consistent efforts in product innovation through research and development buoy optimism. Also, the recent acquisition instills confidence in investors.
BD (BDX) Inks New Deal to Strengthen Foothold in STI Space
by Zacks Equity Research
BD (BDX) is a leading player in providing solutions for women's health and sexually transmitted infections. Its latest development is likely to lend the company a competitive edge in the niche space.
Boston Scientific MultiSENSE Study on HeartLogic Positive
by Zacks Equity Research
Boston Scientific (BSX) positive clinical trial data on HeartLogic should boost the Rhythm Management segment.
Becton, Dickinson Ultra-Fine Needle to Improve Diabetic Care
by Zacks Equity Research
Becton, Dickinson and Company's (BDX) latest micro pen needle will enhance the scope of its Diabetic Care unit.
Neogen (NEOG) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Neogen (NEOG) rides high on balanced growth across all business segments.
Halyard Health (HYH) Announces Positive Data on COOLIEF
by Zacks Equity Research
Halyard Health's (HYH) positive clinical data on COOLIEF will boost fortunes in the chronic pain space.
TransEntrix Progresses Toward FDA Approval for Senhance
by Zacks Equity Research
TransEnterix's (TRXC) gradual progress toward FDA's approval for Senhance Surgical Robotic System will boost its presence in the lucrative U.S. market.
Surmodics Receives FDA's Approval for PTA Balloon Catheter
by Zacks Equity Research
Surmodics (SRDX) receives FDA's approval for PTA Balloon Catheter, which will boost its presence in the global peripheral artery disease market.
Varian Medical (VAR) Releases FDA-Approved Eclipse 15.5
by Zacks Equity Research
Varian Medical (VAR) is consistently trying to turn around its Oncology Systems business.